Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Sanofi”

Early Treatment of Atrial Fibrillation for Stroke Prevention TrialCompleted
NCT01288352Phase 4Updated Jul 23, 2020
Sponsor: Atrial Fibrillation Network
Atrial Fibrillation · Stroke
Belgium, Czechia, Denmark, France, Germany +6 more
Phase 2B Extension Study of Ataluren (PTC124) in Duchenne/Becker Muscular Dystrophy (DMD/BMD)Terminated
NCT00847379Phase 2Updated Jul 15, 2020
Sponsor: PTC Therapeutics
Duchenne Muscular Dystrophy · Becker Muscular Dystrophy
United States, Australia, Belgium, Canada, France +6 more
Ataluren for Nonsense Mutation Methylmalonic AcidemiaTerminated
NCT01141075Phase 2Updated Jul 7, 2020
Sponsor: PTC Therapeutics
Amino Acid Metabolism, Inborn Errors
Belgium, France, Germany, Italy, Switzerland +1 more
Quantitating the Impact of PlerixaforUnknown
NCT02522572Phase 1, Phase 2Updated Jun 30, 2020
Sponsor: E. Steve Woodle
Transplants and Implants
United States
Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)Completed
NCT01709513Phase 3Updated Jun 23, 2020
Sponsor: Regeneron Pharmaceuticals
Hypercholesterolemia
United States, Austria, Canada, France, Israel +3 more
A Study of Alirocumab in Participants With Autosomal Dominant Hypercholesterolemia (ADH) and Gain-of-Function Mutations (GOFm) of the Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Gene or Loss-of-Function Mutations (LOFm) of the Apolipoprotein (Apo) B GeneCompleted
NCT01604824Phase 2Updated Jun 17, 2020
Sponsor: Regeneron Pharmaceuticals
Hypercholesterolemia
United States, France
Study of Ataluren (PTC124) in Hemophilia A and BTerminated
NCT00947193Phase 2Updated Jun 16, 2020
Sponsor: PTC Therapeutics
Hemophilia A · Hemophilia B
United States, Canada, France, Italy
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Lixisenatide on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in JapanCompleted
NCT02749890Phase 3Updated Jun 16, 2020
Sponsor: Sanofi
Type 2 Diabetes Mellitus
Japan
Postprandial Glucodynamic Response to Insulin Glargine/Lixisenatide Fixed Ratio Combination in Japanese Patients With Type 2 Diabetes MellitusCompleted
NCT02713477Phase 1Updated Jun 16, 2020
Sponsor: Sanofi
Type 2 Diabetes Mellitus
Japan
Efficacy and Safety of LixiLan Versus Insulin Glargine Alone Both With Metformin in Japanese With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic DrugsCompleted
NCT02752412Phase 3Updated Jun 16, 2020
Sponsor: Sanofi
Type 2 Diabetes Mellitus
Japan
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Insulin Glargine Alone on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in JapanCompleted
NCT02752828Phase 3Updated Jun 16, 2020
Sponsor: Sanofi
Type 2 Diabetes Mellitus
Japan
Influenza Vaccination Digital Interventions for People Living With DiabetesCompleted
NCT03870997NAUpdated Jun 9, 2020
Sponsor: Evidation Health
Diabetes
United States
Long-term Persistence of Hepatitis B and Pertussis Antibody Responses in Healthy 4 to 5 Year Old Children Previously Vaccinated With Vaxelis® or INFANRIX® Hexa (V419-012)Completed
NCT02759354Phase 3Updated Jun 9, 2020
Sponsor: MCM Vaccines B.V.
Hepatitis B · Pertussis
Prostate Boost Irradiation With Stereotactic Body RT (SBRT)Unknown
NCT03380806Phase 2Updated Jun 4, 2020
Sponsor: Juravinski Cancer Center
Prostate Cancer
Canada
Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic DermatitisCompleted
NCT02277769Phase 3Updated Jun 2, 2020
Sponsor: Regeneron Pharmaceuticals
Dermatitis, Atopic
United States, Canada, France, Germany, Hong Kong +6 more
Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple MyelomaCompleted
NCT00903968Phase 1, Phase 2Updated Jun 2, 2020
Sponsor: Dana-Farber Cancer Institute
Multiple Myeloma
United States
Dupilumab As An Adjunct For Subcutaneous Grass ImmunotherapyCompleted
NCT03558997Phase 2Updated May 28, 2020
Sponsor: Regeneron Pharmaceuticals
Allergic Rhinitis
United States, Canada
Study of Dupilumab and Immune Responses in Adults With Atopic Dermatitis (AD)Completed
NCT02210780Phase 2Updated May 7, 2020
Sponsor: Regeneron Pharmaceuticals
Atopic Dermatitis
United States
Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density Lipoprotein (LDL) Apheresis TherapyCompleted
NCT02326220Phase 3Updated May 1, 2020
Sponsor: Regeneron Pharmaceuticals
Heterozygous Familial Hypercholesterolemia
United States, Germany
Investigating the Effects of Lipid-therapy Intensification With Alirocumab on Endothelial Function, Carotid Arteries, Lipoprotein Particle Subfractions, Inflammation and Post-prandial LipemiaTerminated
NCT03559309Phase 4Updated Apr 24, 2020
Sponsor: Medical University of Graz
Atherosclerosis · Hypercholesterolemia · Post Prandial Lipemia · Cardiovascular Diseases
Austria
Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Older Patients With Type2 Diabetes Insufficiently Controlled on Their Current Antidiabetic MedicationsCompleted
NCT02320721Phase 3Updated Apr 21, 2020
Sponsor: Sanofi
Type 2 Diabetes Mellitus
United States, Argentina, Australia, Canada, Colombia +13 more
An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Melanoma Patients Receiving REGN2810 (Anti-PD-1)Completed
NCT03002376Phase 1Updated Apr 20, 2020
Sponsor: Regeneron Pharmaceuticals
Melanoma
Netherlands, Serbia, South Korea, United Kingdom
Study of Alirocumab (REGN727/SAR236553) added-on to Rosuvastatin Versus Other Lipid Modifying Treatments (LMT) (ODYSSEY OPTIONS II)Completed
NCT01730053Phase 3Updated Apr 7, 2020
Sponsor: Regeneron Pharmaceuticals
Hypercholesterolemia
United States, Australia, Canada, France, Germany +4 more
An Adhesion Reduction Plan in the Management of the Surgical Open AbdomenWithdrawn
NCT01010464NAUpdated Apr 6, 2020
Sponsor: University of Maryland, Baltimore
Open Abdomen
United States
Rapid Elimination Procedure of Teriflunomide With Colestipol HydrochlorideTerminated
NCT02263547Phase 1Updated Apr 3, 2020
Sponsor: Derrick Scott Robertson
Teriflunomide Elimination · Healthy Volunteers
United States

Previous page Next page